Frontlight ResearchEarly access
CompletedNo phase
US Development and Evaluation Study of a Patch-Based PSG System
Key facts
- Who runs it
- Onera BV
- Where
- Birmingham and St Louis, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- People taking part
- 70 people enrolled
- Started
- 4 Aug 2023
- Ended
- 2 Sept 2024
- Type of study
- Interventional
- Treatments tested
- Home PSG Assessment
- Record updated
- 18 March 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- 18 years and older
- Referral for a suspected sleep disorder requiring a sleep diagnostic study
Who cannot take part
- History of allergic reactions to adhesives or hydrogels or a family history of adhesive skin allergies
- Severe skin condition at sites of patch administration such as wounds, burns or on any damaged skin
- Has an implanted cardiac stimulator or diaphragmatic pacer
- Will be exposed to high-frequency surgical equipment, near strong magnetic fields or with devices such as MRIs, external cardiac stimulators during their use of the Onera device
- Inability to provide informed consent
- Has an anatomical abnormality that, in the opinion of the Principal Investigator, makes the subject ineligible for inclusion
Where in United States
- The Sleep Disorders Center of AlabamaBirmingham, United States
- Clayton Sleep InstituteSt Louis, United States
About the trial
What the trial wants to find out
The purpose of this study is continue the development and evaluation of the Onera system as well as the procedures and best practices for dispensing, instruction, use and reportability of results.
The group in the trial
- Home PSG AssessmentTreatment being tested
Testing of the Onera STS in the home environment with the current device shipment method and instructions.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 18 March 2025